All In Biotech

Drug Trial Radar · NCT07918898

Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart

A Phase I Study Comparing Pharmacokinetic/Pharmacodynamic Characteristics and Safety of Single Administration of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Feb 2, 2027

Study completion Feb 2, 2027

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of GZR33 Injection and Insulin Aspart in healthy participants

Conditions

  • Healthy Participants

Interventions

  • GZR101 80 InjectionDrug

    Single dose. Administered s.c.

  • GZR33 InjectionDrug

    Single dose. Administered s.c.

  • Insulin Aspart InjectionDrug

    Single dose. Administered s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCIAsp,0-6hTime frame: 0-6 hours after dosing
  2. AUC GZR33, 0-24hTime frame: 0-24 hours after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Ethics Committee of Bishan Hospital of Chongqing

    Chongqing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.